Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury

Information

• Research Project
• 8832809

• ApplicationId

  8832809

• Core Project Number

  R43NS090664

• Full Project Number

  1R43NS090664-01

• Serial Number

  090664

• FOA Number

  PA-14-071

• Sub Project Id

• Project Start Date

  3/1/2015 - 9 years ago

• Project End Date

  2/28/2017 - 7 years ago

• Program Officer Name

  JAKEMAN, LYN B

• Budget Start Date

  3/1/2015 - 9 years ago

• Budget End Date

  2/28/2017 - 7 years ago

• Fiscal Year

  2015

• Support Year

  01

• Suffix

• Award Notice Date

  2/17/2015 - 9 years ago

Organizations

• BIOAXONE BIOSCIENCES, INC.

DESCRIPTION (provided by applicant): BA-210 is an investigational drug that targets Rho, an intracellular GTPase important for controlling axon regeneration and repair after spinal cord injury. BA-210 has completed a Phase I/IIa clinical trial for treatment of acute spinal cord injury in 48 patients. Not only was BA-210 safe and well tolerated, but patients with cervical SCI showed very promising recovery of arm and hand movements. While current development is to treat acute spinal cord injury, BA-210 has potential to improve outcome in patients with chronic SCI, especially if used in combination with other therapies. One barrier to treating chronic SCI is the glial scar that develops and remains after SCI. Several drugs currently on the market have the potential to digest the glial scar and could be repurposed for SCI. Combining BA-210 with a repurposed drug will accelerate the regulatory path to clinical trials and approval. The overall goal of this SBIR project is to investigate the use of BA-210 in combination with one of two drugs that digest the glial scar as a treatment for chronic SCI.

IC Name

• Activity

  R43

• Administering IC

  NS

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  319201

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  853

• Ed Inst. Type

• Funding ICs

  NINDS:319201\

• Funding Mechanism

  SBIR-STTR RPGs

• Study Section

  ZRG1

• Study Section Name

  Special Emphasis Panel

• Organization Name

  BIOAXONE BIOSCIENCES, INC.

• Organization Department

• Organization DUNS

  968285572

• Organization City

  Cambridge

• Organization State

  MA

• Organization Country

  UNITED STATES

• Organization Zip Code

  021381044

• Organization District

  UNITED STATES